Complete financial analysis of PYC Therapeutics Limited (PYC.AX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of PYC Therapeutics Limited, a leading company in the Biotechnology industry within the Healthcare sector.
- Paradise Co., Ltd. (034230.KQ) Income Statement Analysis – Financial Results
- WU BA Superior Products Holding Group Inc. (WBWB) Income Statement Analysis – Financial Results
- Hypoport SE (HYPOF) Income Statement Analysis – Financial Results
- Esprinet S.p.A. (PRT.MI) Income Statement Analysis – Financial Results
- EKF Diagnostics Holdings plc (EKF.L) Income Statement Analysis – Financial Results
PYC Therapeutics Limited (PYC.AX)
About PYC Therapeutics Limited
PYC Therapeutics Limited, a drug-development company, engages in the discovery and development of drug solutions in the areas of ribonucleic acid therapeutics in Australia. The company's preclinical development programs include VP-001, drug program for retinitis pigmentosa type 11; and PYC-001, a drug program for the treatment of autosomal dominant optic atrophy. It also focuses on the development of programs for kidney, retinal, and central nervous system diseases. PYC Therapeutics Limited has academic-industry collaborations with Murdoch University to support drug discovery and development efforts in the field of neurodegenerative disorders, including Motor Neurone Disease. The company was formerly known as Phylogica Limited and changed its name to PYC Therapeutics Limited in November 2019. PYC Therapeutics Limited was incorporated in 2001 and is based in Nedlands, Australia.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 22.06M | 15.81M | 16.04M | 3.07M | 2.40M | 0.00 | 48.46K | 2.76M | 1.08K | 829.12K | 739.39K | 711.89K | 1.92M | 2.36M | 596.26K | 1.27M | 90.75K | 275.39K | 0.00 | 52.56K |
| Cost of Revenue | 0.00 | 882.05K | 839.51K | 622.36K | 547.11K | 130.56K | 81.30K | 4.67M | 122.12K | 3.58M | 3.62M | 3.27M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 272.50K | 137.23K | 0.00 |
| Gross Profit | 22.06M | 14.92M | 15.20M | 2.45M | 1.85M | -130.56K | -32.84K | -1.91M | -121.04K | -2.75M | -2.88M | -2.55M | 1.92M | 2.36M | 596.26K | 1.27M | 90.75K | 2.89K | -137.23K | 52.56K |
| Gross Profit Ratio | 100.00% | 94.42% | 94.77% | 79.76% | 77.16% | 0.00% | -67.76% | -69.11% | -11,248.98% | -331.60% | -389.52% | -358.88% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 1.05% | 0.00% | 100.00% |
| Research & Development | 56.41M | 35.15M | 24.03M | 14.00M | 5.88M | 4.51M | 6.96M | 4.67M | 4.86M | 4.12M | 4.18M | 4.04M | 0.00 | 0.00 | 0.00 | 0.00 | 2.28M | 0.00 | 1.38M | 407.78K |
| General & Administrative | 4.51M | 4.09M | 6.30M | 7.83M | 3.82M | 1.83M | 1.16M | 1.04M | 903.76K | 541.46K | 433.96K | 1.55M | 1.39M | 1.53M | 1.36M | 1.35M | 2.02M | 1.91M | 1.59M | 1.26M |
| Selling & Marketing | 0.00 | -956.09K | -960.36K | -622.36K | -541.47K | 1.82M | 1.42M | 814.49K | 1.11M | 1.31M | 1.37M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 19.93K | 0.00 |
| SG&A | 4.51M | 3.14M | 5.34M | 7.21M | 3.28M | 2.46M | 2.72M | 1.85M | 973.56K | 1.86M | 1.80M | 1.55M | 1.39M | 1.53M | 1.36M | 1.35M | 2.02M | 1.91M | 1.59M | 1.26M |
| Other Expenses | 0.00 | 15.75M | 15.92M | 3.13M | 62.50K | 250.00 | 48.46K | 2.76M | 1.08K | 65.74K | 47.24K | 711.89K | 4.60M | 4.55M | 3.90M | 3.63M | 783.62K | 605.47K | 33.77K | 127.42K |
| Operating Expenses | 60.92M | 38.28M | 29.37M | 21.21M | 9.15M | 6.97M | 9.69M | 2.34M | 5.83M | 2.28M | 2.26M | 6.10M | 5.98M | 6.08M | 5.26M | 4.98M | 5.66M | 4.70M | 3.94M | 1.79M |
| Cost & Expenses | 60.92M | 39.16M | 30.21M | 21.83M | 9.70M | 7.10M | 9.77M | 7.01M | 5.95M | 5.86M | 5.88M | 6.10M | 5.98M | 6.08M | 5.26M | 4.98M | 5.66M | 4.97M | 4.08M | 1.79M |
| Interest Income | 795.98K | 81.85K | 24.43K | 108.50K | 207.03K | 117.96K | 114.88K | 75.86K | 178.68K | 75.32K | 86.48K | 73.78K | 161.55K | 112.52K | 91.66K | 104.42K | 306.26K | 201.63K | 231.82K | 111.29K |
| Interest Expense | 49.21K | 27.29K | 32.60K | 38.82K | 42.92K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.07M | 882.05K | 839.51K | 622.36K | 547.11K | 130.56K | 81.30K | 55.26K | 122.12K | 212.24K | 214.26K | 274.17K | 196.30K | 154.54K | 66.94K | 114.03K | 49.48K | 26.28K | 18.14K | 42.30K |
| EBITDA | -38.12M | -38.25M | -29.39M | -21.04M | -8.89M | -6.97M | -9.64M | -4.20M | -6.10M | -4.82M | -4.92M | -5.04M | -3.87M | -3.56M | -4.60M | -3.59M | -5.52M | -4.67M | -3.59M | -1.70M |
| EBITDA Ratio | -172.80% | -242.19% | -183.06% | -689.91% | -382.13% | 0.00% | -19,989.37% | -151.89% | -541,715.61% | -581.47% | -665.67% | -819.00% | -201.72% | -151.08% | -771.07% | -211.44% | -6,087.29% | -1,695.62% | 0.00% | -3,232.01% |
| Operating Income | -38.86M | -39.16M | -30.21M | -21.83M | -9.70M | -7.10M | -9.77M | -4.25M | -5.95M | -5.03M | -5.14M | -6.10M | -4.07M | -3.72M | -4.66M | -3.70M | -5.57M | -4.70M | -4.08M | -1.74M |
| Operating Income Ratio | -176.15% | -247.77% | -188.29% | -710.16% | -404.97% | 0.00% | -20,157.14% | -153.89% | -553,065.06% | -607.06% | -694.64% | -857.51% | -211.95% | -157.63% | -782.30% | -290.41% | -6,141.81% | -1,705.17% | 0.00% | -3,312.50% |
| Total Other Income/Expenses | -16.81M | -15.73M | -8.17K | -2.94M | 226.61K | 118.21K | 6.64M | 78.34K | -94.94K | -74.89K | 133.72K | 73.78K | 161.55K | 112.52K | 91.66K | -788.35K | 1.09M | 807.10K | 254.25K | 153.60K |
| Income Before Tax | -55.67M | -39.16M | -30.27M | -21.70M | -9.48M | -6.98M | -9.60M | -4.18M | -6.05M | -4.96M | -5.05M | -5.32M | -3.90M | -3.61M | -4.57M | -4.49M | -4.48M | -3.89M | -4.28M | -1.59M |
| Income Before Tax Ratio | -252.36% | -247.77% | -188.66% | -705.87% | -395.51% | 0.00% | -19,820.08% | -151.15% | -561,888.48% | -597.98% | -682.95% | -747.15% | -203.53% | -152.86% | -766.92% | -352.25% | -4,940.87% | -1,412.09% | 0.00% | -3,020.25% |
| Income Tax Expense | -17.56M | -15.81M | -15.97M | -3.07M | -2.40M | -2.90M | -2.17M | 2.22M | -2.07M | 1.97M | 1.79M | -1.88M | 0.00 | 0.00 | 0.00 | 788.35K | -306.26K | -201.63K | -286.01K | -1.59M |
| Net Income | -37.73M | -22.79M | -13.86M | -17.77M | -6.82M | -4.08M | -7.43M | -1.95M | -3.98M | -2.99M | -3.26M | -3.44M | -3.90M | -3.61M | -4.57M | -4.49M | -4.48M | -3.89M | -3.99M | -1.59M |
| Net Income Ratio | -171.02% | -144.18% | -86.41% | -577.93% | -284.77% | 0.00% | -15,340.48% | -70.61% | -369,765.06% | -360.80% | -440.59% | -483.17% | -203.53% | -152.86% | -766.92% | -352.25% | -4,940.87% | -1,412.09% | 0.00% | -3,020.25% |
| EPS | -0.01 | -0.01 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.01 | -0.01 | 0.00 | -0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 3.93B | 3.25B | 3.22B | 3.13B | 2.80B | 2.80B | 2.22B | 2.80B | 1.96B | 2.80B | 2.80B | 2.80B | 2.80B | 2.80B | 2.80B | 2.80B | 2.80B | 2.80B | 2.80B | 2.80B |
| Weighted Avg Shares Out (Dil) | 3.94B | 3.25B | 3.22B | 3.13B | 2.80B | 2.80B | 2.22B | 2.80B | 1.96B | 2.80B | 2.80B | 2.80B | 2.80B | 2.80B | 2.80B | 2.80B | 2.80B | 2.80B | 2.80B | 2.80B |
Source: https://incomestatements.info
Category: Stock Reports